NCT02779777View on ClinicalTrials.gov

Tipifarnib in Subjects With Myelodysplastic Syndromes

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

August 28, 2018

Study Completion Date

August 28, 2018

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Tipifarnib

Oral tablet

Trial Locations (2)

10032

Columbia University Medical Center, New York

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Kura Oncology, Inc.

INDUSTRY